Key Takeaways:
- ADMA Biologics faces a securities class action lawsuit after a 29% stock decline
- The suit alleges channel stuffing inflated revenue before the practice was uncovered
- Investors have until Aug. 10 to apply for lead plaintiff status
戻る
ADMA Biologics faces class action after 29% stock drop on channel stuffing claims
ADMA Biologics investors filed a securities class action lawsuit after the stock plunged 29% on channel stuffing allegations.
"The lawsuit accuses the company and senior executives of violating federal securities laws," Bleichmar Fonti & Auld LLP, the law firm representing investors, said in a statement.
The complaint centers on allegations that ADMA engaged in channel stuffing — inflating revenue by pushing excess product into its distribution network — before the practice was uncovered, triggering the selloff. Multiple law firms including Pomerantz LLP and Kahn Swick & Foti LLC have issued investor notices with an Aug. 10 lead plaintiff deadline.
The 29% decline represents one of the steepest single-day drops for a biopharmaceutical company this year, exposing ADMA to potential financial penalties, reputational damage, and heightened regulatory scrutiny. The company, which specializes in plasma-derived biologics for immune-deficient patients, now faces a class period yet to be defined by the court.
The lawsuit adds to a growing wave of securities fraud claims targeting biotech and pharmaceutical companies over revenue recognition practices. Investors who purchased ADMA shares during the relevant period have until Aug. 10 to apply for lead plaintiff status. The case will be heard in federal court, with a judge expected to appoint a lead plaintiff in the coming months.
This article is for informational purposes only and does not constitute investment advice.
[1] $ADMA Investor Loss Alert: ADMA Biologics Investors may have been Misled after Channel Stuffing Claims Lead to 29% Stock Drop – Contact BFA Law if You Lost Money[2] ADMA Shareholder Alert: ADMA Biologics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm[3] ADMA Court News: ADMA Biologics Class Action Lawsuit Alleges Securities Fraud on behalf of Investors with Losses[4] INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA ...[5] ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - ...
